S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
NASDAQ:AFIB

Acutus Medical Stock Forecast, Price & News

$2.66
-0.36 (-11.92%)
(As of 01/14/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.51
$2.83
50-Day Range
$2.66
$7.83
52-Week Range
$2.51
$29.95
Volume
759,396 shs
Average Volume
417,430 shs
Market Capitalization
$74.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.58
30 days | 90 days | 365 days | Advanced Chart
Receive AFIB News and Ratings via Email

Sign-up to receive the latest news and ratings for Acutus Medical and its competitors with MarketBeat's FREE daily newsletter.


Acutus Medical logo

About Acutus Medical

Acutus Medical, Inc., an arrhythmia management company, designs, manufactures, and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. Its product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact force ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. Acutus Medical, Inc. was incorporated in 2011 and is based in Carlsbad, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AFIB
Employees
291
Year Founded
N/A

Sales & Book Value

Annual Sales
$8.46 million
Book Value
$4.55 per share

Profitability

Net Income
$-101.98 million
Net Margins
-748.44%
Pretax Margin
-748.29%

Debt

Price-To-Earnings

Miscellaneous

Free Float
21,132,000
Market Cap
$74.35 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/11/2021
Today
1/17/2022
Next Earnings (Estimated)
3/17/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.61 out of 5 stars

Medical Sector

80th out of 1,417 stocks

Surgical & Medical Instruments Industry

12th out of 130 stocks

Analyst Opinion: 4.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 5.0Valuation: 1.3 5 -4 -3 -2 -1 -












Acutus Medical (NASDAQ:AFIB) Frequently Asked Questions

Is Acutus Medical a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Acutus Medical in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Acutus Medical stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AFIB, but not buy additional shares or sell existing shares.
View analyst ratings for Acutus Medical
or view top-rated stocks.

Are investors shorting Acutus Medical?

Acutus Medical saw a drop in short interest in December. As of December 15th, there was short interest totaling 670,800 shares, a drop of 23.8% from the November 30th total of 880,800 shares. Based on an average daily volume of 491,600 shares, the days-to-cover ratio is presently 1.4 days. Approximately 3.5% of the shares of the company are short sold.
View Acutus Medical's Short Interest
.

When is Acutus Medical's next earnings date?

Acutus Medical is scheduled to release its next quarterly earnings announcement on Thursday, March 17th 2022.
View our earnings forecast for Acutus Medical
.

How were Acutus Medical's earnings last quarter?

Acutus Medical, Inc. (NASDAQ:AFIB) issued its earnings results on Thursday, November, 11th. The company reported ($0.94) EPS for the quarter, missing the Zacks' consensus estimate of ($0.92) by $0.02. The firm earned $4.60 million during the quarter, compared to analysts' expectations of $6.02 million. Acutus Medical had a negative net margin of 748.44% and a negative trailing twelve-month return on equity of 107.24%. During the same period last year, the business posted ($1.18) EPS.
View Acutus Medical's earnings history
.

What guidance has Acutus Medical issued on next quarter's earnings?

Acutus Medical updated its FY 2021 earnings guidance on Friday, December, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $17 million-$17.50 million, compared to the consensus revenue estimate of $22.46 million.

What price target have analysts set for AFIB?

6 brokerages have issued 12-month price objectives for Acutus Medical's stock. Their forecasts range from $3.00 to $19.00. On average, they anticipate Acutus Medical's share price to reach $11.80 in the next year. This suggests a possible upside of 343.6% from the stock's current price.
View analysts' price targets for Acutus Medical
or view top-rated stocks among Wall Street analysts.

Who are Acutus Medical's key executives?

Acutus Medical's management team includes the following people:
  • Mr. R. Scott Huennekens M.B.A., CPA, Exec. Chairman (Age 57, Pay $179.44k)
  • Mr. Vincent J. Burgess, Pres, CEO & Director (Age 56, Pay $581.27k)
  • Mr. Gary W. Doherty, Sr. VP of Fin. (Age 54, Pay $434.32k)
  • Mr. David Harrison Roman, Sr. VP & CFO (Age 39)
  • Mr. Richard M. Kimes, Sr. VP of Operations (Age 59)
  • Dr. Graydon E. Beatty, Chief Technology Officer (Age 64)
  • Dr. Derrick Chou Ph.D., Chief Technology Officer
  • Mr. Tom Sohn, Sr. VP, Gen. Counsel & Sec. (Age 46)
  • Mr. Charlie Piscitello, Chief People Officer (Age 58)
  • Mr. Tim Corvi, Sr. VP of R&D (Age 52)

What other stocks do shareholders of Acutus Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acutus Medical investors own include Oak Street Health (OSH), Alibaba Group (BABA), Checkmate Pharmaceuticals (CMPI), salesforce.com (CRM), Walt Disney (DIS), DocuSign (DOCU), Marvell Technology (MRVL), NVIDIA (NVDA), Tesla (TSLA) and Twilio (TWLO).

When did Acutus Medical IPO?

(AFIB) raised $126 million in an IPO on Thursday, August 6th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, BofA Securities and William Blair acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

What is Acutus Medical's stock symbol?

Acutus Medical trades on the NASDAQ under the ticker symbol "AFIB."

Who are Acutus Medical's major shareholders?

Acutus Medical's stock is owned by a variety of retail and institutional investors. Top institutional investors include S.A. Mason LLC (0.03%). Company insiders that own Acutus Medical stock include James F Hinrichs and Orbimed Advisors Llc.
View institutional ownership trends for Acutus Medical
.

Which institutional investors are selling Acutus Medical stock?

AFIB stock was sold by a variety of institutional investors in the last quarter, including S.A. Mason LLC.
View insider buying and selling activity for Acutus Medical
or view top insider-selling stocks.

How do I buy shares of Acutus Medical?

Shares of AFIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Acutus Medical's stock price today?

One share of AFIB stock can currently be purchased for approximately $2.66.

How much money does Acutus Medical make?

Acutus Medical has a market capitalization of $74.35 million and generates $8.46 million in revenue each year. The company earns $-101.98 million in net income (profit) each year or ($4.05) on an earnings per share basis.

How many employees does Acutus Medical have?

Acutus Medical employs 291 workers across the globe.

What is Acutus Medical's official website?

The official website for Acutus Medical is www.acutusmedical.com.

Where are Acutus Medical's headquarters?

Acutus Medical is headquartered at 2210 FARADAY AVE SUITE 100, CARLSBAD CA, 92008.

How can I contact Acutus Medical?

Acutus Medical's mailing address is 2210 FARADAY AVE SUITE 100, CARLSBAD CA, 92008. The company can be reached via phone at 442-232-6080, via email at [email protected], or via fax at 442-232-6081.


This page was last updated on 1/17/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.